Europe's consumer health industry is faced with proliferating regulations under the EU's Green Deal policy program. Proposed revisions to the Urban Wastewater Treatment Directive, for example, expect pharmaceutical and cosmetics manufacturers to pay for the removal of micro-pollutants that are mostly flushed into the wastewater system by consumers. While the European Commission says it is “sympathetic” to industry's concerns, such as those raised at the AESGP Annual Meeting and in recent publications, its director for zero pollution and green cities, Veronica Manfredi, stressed that “there are no excuses, there can be no business as usual” given the urgency of the situation.
• Source: Shutterstock
There can be “no excuses, no business as usual” from the consumer health industry when it comes to achieving the EU’s zero pollution ambitions.
This was the uncompromising message from the European Commission, whose director for zero pollution and green cities, Veronica Manfredi, addressed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”
At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.
Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”
AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.
AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.
An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.
